Search Results
Your search for Colorectal matches 3172 pages
Showing 3151 - 3172Investigational New Drug Application Filed for CFI-400945
Investigators from Princess Margaret Cancer Centre in Toronto and the University of California, Los Angeles, have submitted an Investigational New Drug (IND) application for CFI-400945, a novel drug candidate targeting the enzyme PLK4, which plays a crucial role in cell division. The news was...
Impact of Age on Efficacy of Newer Adjuvant Therapies in Patients with Stage II/III Colon Cancer
Available data suggest that patients with stage II/III colon cancer receive similar benefit from intravenous fluorouracil (5-FU) adjuvant therapy regardless of age. Combination regimens and oral fluoropyrimidine therapy are now standard treatments in this setting. Nadine J. McCleary, MD, MPH, and...
ASCO 2013: Genomic Heterogeneity Can Lead to the Selection of ‘Incorrect’ Targeted Inhibitors
Genomic heterogeneity within tumors and among lesions varies widely, and “discordance among lesions could lead to the selection of the ‘incorrect’ targeted inhibitor,” according to David B. Solit, MD, of Memorial Sloan-Kettering Cancer Center, who spoke at the ASCO/American...
ASCO 2013: Lung Cancer Mutations ALK and ROS1 Also Drive Colorectal Cancer
A study from the University of Colorado Cancer Center shows that the ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. Results imply that drugs used to target ALK and ROS1 in lung cancer may also have applications in this subset of...
ASCO 2013: Cetuximab Offers Survival Advantage over Bevacizumab When Combined with FOLFIRI for First-line Treatment of Advanced Colorectal Cancer
First-line cetuximab (Erbitux) plus FOLFIRI chemotherapy (leucovorin, fluorouracil [5-FU], irinotecan) offered a roughly 4-month survival advantage over bevacizumab (Avastin) plus FOLFIRI for patients with KRAS wild-type metastatic colorectal cancer in the German phase III clinical trial FIRE-3. A ...
ASCO 2013: For Patients with Metastatic Pancreatic Cancer, Both Treatment and Survival Decrease with Advanced Age
A new study by researchers Fox Chase Cancer Center has identified a disconnect between clinical trials that look at new treatments for metastatic pancreatic cancer and the patient population most likely to be diagnosed with the disease. Clinical trials typically enroll, and base their findings on,...
ASCO 2013: Anti–PD-L1 Drug Shows Promising Anticancer Effects in a Variety of Advanced Cancers
A phase I expansion study of the investigational drug MPDL3280A— an engineered PD-L1 targeted antibody—shows impressive tumor shrinkage rates in patients with several different cancers—including lung, melanoma, kidney, colorectal, and gastric cancers—that had progressed...
ASCO 2013: Men’s Fitness in Middle Age Protects against Developing and Dying from Cancer Later in Life
Findings from a large, prospective 20-year study indicate that a high level of cardiovascular fitness in middle age reduces men’s risk of developing and dying from lung and colorectal cancer, two of the most common cancers affecting men. Better fitness also reduces the risk of dying from,...
Study Establishes Basis for Genomic Classification of Endometrial Cancers
A comprehensive genomic analysis of nearly 400 endometrial tumors suggests that certain molecular characteristics, such as the frequency of mutations, could complement current pathology methods and help distinguish between principal types of endometrial tumors, as well as provide insights into...
Experimental Drug Beneficial in NIH Trial to Treat a Rare Sarcoma
Patients with advanced alveolar soft part sarcoma achieved some control of their disease using the experimental anticancer drug cediranib. The results from this largest clinical trial on alveolar soft part sarcoma to date were published online ahead of print on April 29, 2013, in the Journal of...
Women Smokers May Have Greater Risk for Colon Cancer Than Men
Smoking increased the risk for developing colon cancer, and female smokers may have a greater risk than male smokers, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. “Globally, during the last 50...
Adding Cetuximab to Chemotherapy Enables Select Patients with Advanced Colorectal Cancer and Liver Metastasis to Undergo Surgery
New results from a clinical trial conducted in Shanghai, China, indicate that adding cetuximab (Erbitux) to standard chemotherapy enables some patients with otherwise inoperable liver metastases due to colorectal cancer have their metastases surgically removed. Such surgery can be curative, and is...
Roswell Park Scientists Advance Findings about Novel, Low-toxicity Anticancer Agent
Researchers at Roswell Park Cancer Institute (RPCI) have found that a new formulation of a promising anticancer agent, the small chemical molecule FL118, is even more effective in controlling two types of cancer than a version reported in PLOS ONE 6 months earlier proved to be. Additional evidence...
Prostate Cancer Risk Rises in Men with Lynch Syndrome
Men with Lynch syndrome face a higher lifetime risk of developing prostate cancer and appear to develop the disease at an earlier age, according to a new study led by researchers at the University of Michigan Comprehensive Cancer Center. Results of the study appear online in the Journal of Clinical ...
Cancer Drug Shortages Mean Higher Costs and Greater Risk for Patients
A national survey of health professionals showed that drug shortages are taking a heavy toll on cancer patients, forcing treatment changes and delays that for some patients meant worse outcomes, more therapy-related complications, and higher costs. St. Jude Children’s Research Hospital...
Colon Cancer Patient Advocates and Physicians Urge Congress to Pass Bill Requiring Medicare Coverage of Virtual Colonoscopy
As Americans celebrate National Colorectal Cancer Awareness Month, the Colon Cancer Alliance, COLONTOWN—a survivor/patient support group for colorectal disease, including cancer—and the American College of Radiology call on Congress to pass the CT Colonography Screening...
Colonoscopy Screening Reduces Risk of Advanced Colorectal Cancer, Study Shows
A new study led by a researcher at the Perelman School of Medicine at the University of Pennsylvania adds support to current medical recommendations stating that colonoscopy screening substantially reduces an average-risk adult’s likelihood of being diagnosed with advanced colorectal...
Obesity, Physical Inactivity Linked with Risk for Certain Molecular Subtype of Colorectal Cancer
An increasing body mass index (BMI) was associated with a higher risk for colorectal cancer with a specific molecular characteristic, and inversely, physical activity was linked to a decreased risk for that same cancer, according to data published in Cancer Research, a journal of the American...
FDA Approves Regorafenib for Advanced Gastrointestinal Stromal Tumors
The FDA has expanded the approved use of regorafenib (Stivarga) to treat patients with metastatic or unresectable gastrointestinal stromal tumors (GIST) that no longer respond to treatment with imatinib (Gleevec) or sunitinib (Sutent). Regorafenib, a multikinase inhibitor, blocks several enzymes...
Researchers Identify Variations in Four Genes That Are Associated with an Increased Risk of Colorectal Cancer
An international research team co-led by cancer prevention researcher Ulrike Peters, PhD, MPH, and biostatistician Hsu Li, PhD, at Fred Hutchinson Cancer Research Center has identified variations in four genes that are linked to an increased risk of colorectal cancer. Dr. Peters and...
Bevacizumab Approved as Combination Therapy for Metastatic Colorectal Cancer after Progression on First-line Bevacizumab Therapy
On January 23, 2013, the FDA approved bevacizumab (Avastin) for use in combination with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy for the treatment of patients with metastatic colorectal cancer whose disease has progressed on a first-line bevacizumab-containing...
New Model May Help Predict Response to Chemotherapy for Colorectal Cancer
Scientists may be able to better predict which patients with colorectal cancer will respond to chemotherapy using a new mathematical model that measures the amount of stress required for a cancer cell to die without harming healthy tissue. The results of this study are published in Cancer Research, ...
